Prebiotic (oligofructose-enriched inulin) in children with T1DM: a pilot RCT
Twelve weeks of oligofructose-enriched inulin supplementation did not significantly improve HbA1c in Indian children with T1DM, despite inducing shifts in gut microbiome composition.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
No statistically significant difference in HbA1c was found between groups at endpoint (prebiotic 9.8% vs. placebo 10.6%; p > 0.05). The prebiotic group showed significant enrichment of SCFA-producing taxa, including Intestinibacter, Lachnospiraceae_UCG004, Megasphaera, Prevotella_2, and Agathobacter. The primary glycemic outcome was negative; microbiome changes were a secondary finding.
How it was done
Double-blind, randomised, placebo-controlled pilot trial; 68 children (8–18 years) with established T1DM received 8 g/day of oligofructose-enriched inulin or isocaloric maltodextrin for 12 weeks. Fecal microbiome assessed by 16S rRNA sequencing with alpha/beta diversity and differential abundance analyses (DESeq2).
Risk of bias
Pilot design with small sample (61 completers) provides insufficient statistical power for glycemic outcomes. The exclusively Indian sample limits generalizability; 12 weeks may be inadequate to detect clinically relevant HbA1c changes.
What this study does NOT prove
It cannot be concluded that enrichment of SCFA-producing taxa translates into measurable clinical benefit for glycemic control in pediatric T1DM.
In clinical practice
Findings do not support clinical use of oligofructose-enriched inulin for glycemic control in pediatric T1DM. Observed microbiome changes are preliminary and lack established clinical correlation.
Limitations
Pilot design with small sample (61 completers) provides insufficient statistical power for glycemic outcomes. The exclusively Indian sample limits generalizability; 12 weeks may be inadequate to detect clinically relevant HbA1c changes.
Technical appendix
Version history
- 1.0 · 2026-07-06 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.